Get the Stockscreener App
371.58
3.70%
13.26
Pre-market:
374.64
3.06
+0.82%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $371.58, with a volume of 2.29M.
It is up +3.70% in the last 24 hours and up +6.82% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$358.32
Open:
$358.245
24h Volume:
2.29M
Relative Volume:
0.87
Market Cap:
$200.54B
Revenue:
$37.30B
Net Income/Loss:
$7.80B
P/E Ratio:
25.84
EPS:
14.3793
Net Cash Flow:
$8.60B
1W Performance:
+2.19%
1M Performance:
+6.82%
6M Performance:
+12.46%
1Y Performance:
+24.27%
1-Day Range:
$357.74
$372.14
1-Week Range:
$353.95
$372.14
52-Week Range:
$269.77
$391.29
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
371.58 | 200.54B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,169.17 | 1.04T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
249.97 | 601.73B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
254.39 | 449.45B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
127.63 | 315.22B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
152.73 | 291.42B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Hold |
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Assetmark Inc. Purchases 15,719 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen stock trades steadily as recent earnings and pipeline progress shape sentiment - ad-hoc-news.de
Amgen Inc (AMGN) Stock Up 3.7% but GF Value Says Overvalued -- G - GuruFocus
Amgen stock advances after cardiovascular data and solid Q1 2026 growth - ad-hoc-news.de
Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Wealthfront Advisers LLC Boosts Position in Amgen Inc. $AMGN - MarketBeat
D.A. Davidson & CO. Trims Stake in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by Bank of New York Mellon Corp - MarketBeat
(AMGN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Landmark ECOG-ACRIN ENDURANCE Study Co-Authored by International Myeloma Foundation Leaders Provides Evidence for Optimal Duration of Maintenance Therapy - GlobeNewswire Inc.
Amgen stock holds steady as biotech pipeline and US revenue base anchor long-term story - Ad Hoc News
Amgen’s Tablet Recalls Test Its Quality Controls and Manufacturing Ambitions (AMGN) - simplywall.st
Livforsakringsbolaget Skandia Omsesidigt Purchases 10,752 Shares of Amgen Inc. $AMGN - MarketBeat
Principal Financial Group Inc. Increases Stock Position in Amgen Inc. $AMGN - MarketBeat
AMG National Trust Bank Has $4.59 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance
Amgen Inc. stock outperforms competitors despite losses on the day - MarketWatch
After Antibiotic Approval, Spero Pivots to Immunology Aiming to Rival an Amgen Asset - MedCity News
Amgen Colo. Win May Chill States' Push To Cap Drug Prices - Law360
Pfizer Vs. Amgen: Bet That Pfizer's Seagen Integration Leads to Long-Term Oncology Alpha Over Amgen - 24/7 Wall St.
Amgen (AMGN) Stock May Be 47% Undervalued After Enbrel Price Cap Ruling - Yahoo Finance
Amgen stock holds steady as biotech pipeline and US market presence shape the long-term story - Ad-hoc-news.de
Amgen Inc. $AMGN Shares Sold by Mattern Capital Management LLC - MarketBeat
Calamos Advisors LLC Buys 3,648 Shares of Amgen Inc. $AMGN - MarketBeat
Advancements in CKD Care: How New Therapies from AstraZeneca, Johnson & Johnson, Novartis, Bayer, and Amgen Are Changing the Landscape - Yahoo Finance Singapore
Bleakley Financial Group LLC Purchases 3,526 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen (AMGN) Recalls Corlanor And Sensipar Nationwide Over Quality Control Issues - simplywall.st
Amgen Faces a July 29 Deadline to Save Tavneos From an FDA Withdrawal. Here’s What It Means for the Stock. - TIKR.com
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Guggenheim Issues Positive Forecast for Amgen (NASDAQ:AMGN) Stock Price - MarketBeat
Guggenheim raises Amgen stock price target to $343 on product mix - Investing.com
AMGN DCF Analysis: Intrinsic Value $292 vs Price $363 - GuruFocus
BofA raises Amgen stock price target on growth franchise execution By Investing.com - Investing.com Nigeria
BofA raises Amgen stock price target on growth franchise execution - Investing.com
J. Safra Sarasin Holding AG Sells 38,033 Shares of Amgen Inc. $AMGN - MarketBeat
Absher Wealth Management LLC Trims Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen stock holds steady as biotech pipeline and U.S. market presence underpin long-term story - ad-hoc-news.de
Castleview Partners LLC Has $2.77 Million Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Acquired by Ferguson Wellman Capital Management Inc. - MarketBeat
Cullinan Associates Inc. Has $8.98 Million Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Fifth Third Bancorp Acquires 167,835 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen stock holds steady as investors await the next catalyst - ad-hoc-news.de
Amgen stock steadies as the biotech group leans on scale - ad-hoc-news.de
Amgen Inc. $AMGN Shares Sold by Torray Investment Partners LLC - MarketBeat
Candriam S.C.A. Raises Holdings in Amgen Inc. $AMGN - MarketBeat
Conning Inc. Has $33.85 Million Position in Amgen Inc. $AMGN - MarketBeat
Amgen stock holds steady as biotech pipeline and U.S. market listing shape long-term investor expect - ad-hoc-news.de
Amgen's Biotech Crossroads: Congressional Divergence Amid Patent Cliffs and Pipeline Promise - Kavout | AI
ETFs Investing in Amgen Inc. Stocks - TradingView
Amgen stock holds steady as biotech pipeline and U.S. market presence underpin long-term growth narr - ad-hoc-news.de
Amgen stock reflects biotech heavyweight's steady role in US healthcare - ad-hoc-news.de
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):